Prevalence of drug-resistant and nonsubtype B HIV strains in antiretroviral-naïve, HIV-infected individuals in New York State

AIDS Patient Care and STDs

Volumn 21, Issue 9, 2007, Pages 644-652

  Parker, Monica M ^a   Gordon, Daniel ^b   Reilly, Andrew ^a,c   Horowitz, Harold W ^d   Waters, Mark ^b   Bennett, Ryan ^a   Hallack, Renee ^a   Smith, Joseph ^a   Lamson, Daryl ^a   Aydemir, Aida ^a,c   Dvali, Natia ^a   Agins, Bruce D ^b   Drusano, George L ^a,e   Taylor, Jill ^a  

^a WADSWORTH CENTER   (United States)

^b NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^c UNIVERSITY AT ALBANY   (United States)

^d WESTCHESTER MEDICAL CENTER   (United States)

^e ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CITY; COHORT ANALYSIS; CONFIDENCE INTERVAL; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTPATIENT DEPARTMENT; PREVALENCE; SEQUENCE ANALYSIS; UNITED STATES; VIRUS MUTATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ADULT; AGED; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; NEW YORK; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 34948831019     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.0172     Document Type: Article

References (34)

1. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001;322:1087-1088.
2. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999;282:1135-1141.
3. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181-188.
4. Little SJ, Daar ES, D'Aquila RT, et al. Reduced anti-retroviral drug susceptibility among patients with primary HIV infection. JAMA 1999;282:1142-1149.
5. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
6. Wegner SA, Brodine SK, Mascola JR, et al. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS 2000;14:1009-1015.
7. Weinstock H, Respess R, Heneine W, et al. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. J Infect Dis 2000;182:330-333.
8. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999;354:729-733.
9. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: Clinical impact and cost-effectiveness. Ann Intern Med 2001;134:440-450.
10. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf Accessed October 10, 2006.
11. Hanna GJ, Balaguera HU, Freedberg KA, et al. Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive adults with established human immunodeficiency virus infection. J Infect Dis 2003;188:986-991.
12. Novak RM, Chen L, MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: Implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005;40:468-474.
13. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004;189:2174-2180.
14. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med 2005;13:51-57.
15. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.
16. Kumar S, Tamura K, Nei M. MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 2004;5:150-163.
17. Schroeder TL, Burger H, Weiser B, et al. Characterization of intersubtype recombinant HIV type 1 genomes using a nonradioactive heteroduplex tracking assay. AIDS Res Hum Retroviruses 2005;21:314-318.
18. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: A decade of experience. J Acquir Immune Defic Syndr 2006;41:439-446.
19. Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005;41:1316-1323.
20. Achkar JM, Burda ST, Konings FA, et al. Infection with HIV type 1 group M non-B subtypes in individuals living in New York City. J Acquir Immune Defic Syndr 2004;36:835-844.
21. Sides TL, Akinsete O, Henry K, Wotton JT, Carr PW, Bartkus J. HIV-1 subtype diversity in Minnesota. J Infect Dis 2005;192:37-45.
22. Weidle PJ, Ganea CE, Irwin KL, et al. Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: A sentinel site for monitoring HIV genetic diversity in the United States. J Infect Dis 2000;181:470-475.
23. Karchava M, Pulver W, Smith L, et al. Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State. J Acquir Immune Defic Syndr 2006;42:614-619.
24. Geretti AM. HIV-1 subtypes: Epidemiology and significance for HIV management. Curr Opin Infect Dis 2006;19:1-7.
25. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999;13:F123-127.
26. Miller V. Structured treatment interruptions in anti-retroviral management of HIV-1. Curr Opin Infect Dis 2001;14:29-37.
27. Brenner BG, Routy JP, Petrella M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002;76:1753-1761.
28. Chan KC, Galli RA, Montaner JS, Harrigan PR. Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection. AIDS 2003;17:1256-1258.
29. Little SJ, Dawson K, Hellmann NS, et al. Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring antiretroviral therapy. Antivir Ther 2003;8:5129(Abst. 115).
30. Barbour JD, Hecht FM, Wrin T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004;18:1683-1689.
31. Pao D, Andrady U, Clarke J, et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004;37:1570-1573.
32. Devereux HL, Emery VC, Johnson MA, Loveday C. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol 2001;65:218-224.
33. Miller V, Stark T, Loeliger AE, Lange JM. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med 2002;3:135-145.
34. Turner D, Brenner B, Routy JP, et al. Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr 2004;37:1627-1631.